- Home
- QLGN vs NAOV Comparison
QLGN vs NAOV Comparison
Compare QLGN & NAOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QLGN
- NAOV
- Stock Information
- Founded
- QLGN 1996
- NAOV 2003
- Country
- QLGN United States
- NAOV United States
- Employees
- QLGN N/A
- NAOV N/A
- Industry
- QLGN Biotechnology: Pharmaceutical Preparations
- NAOV Industrial Specialties
- Sector
- QLGN Health Care
- NAOV Health Care
- Exchange
- QLGN Nasdaq
- NAOV Nasdaq
- Market Cap
- QLGN 2.8M
- NAOV 2.4M
- IPO Year
- QLGN N/A
- NAOV N/A
- Fundamental
- Price
- QLGN $3.16
- NAOV $0.93
- Analyst Decision
- QLGN
- NAOV
- Analyst Count
- QLGN 0
- NAOV 0
- Target Price
- QLGN N/A
- NAOV N/A
- AVG Volume (30 Days)
- QLGN 10.7K
- NAOV 8.2M
- Earning Date
- QLGN 08-13-2025
- NAOV 08-13-2025
- Dividend Yield
- QLGN N/A
- NAOV N/A
- EPS Growth
- QLGN N/A
- NAOV N/A
- EPS
- QLGN N/A
- NAOV N/A
- Revenue
- QLGN N/A
- NAOV $2,662,000.00
- Revenue This Year
- QLGN N/A
- NAOV N/A
- Revenue Next Year
- QLGN N/A
- NAOV N/A
- P/E Ratio
- QLGN N/A
- NAOV N/A
- Revenue Growth
- QLGN N/A
- NAOV N/A
- 52 Week Low
- QLGN $2.85
- NAOV $0.67
- 52 Week High
- QLGN $29.44
- NAOV $16.25
- Technical
- Relative Strength Index (RSI)
- QLGN 32.55
- NAOV 39.35
- Support Level
- QLGN $3.37
- NAOV $0.90
- Resistance Level
- QLGN $3.70
- NAOV $1.32
- Average True Range (ATR)
- QLGN 0.21
- NAOV 0.08
- MACD
- QLGN -0.05
- NAOV 0.10
- Stochastic Oscillator
- QLGN 0.00
- NAOV 18.75
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.
About NAOV NanoVibronix Inc.
NanoVibronix Inc manufactures noninvasive biological response-activating devices that target biofilm prevention, pain therapy, and wound healing and can be administered at home, without the assistance of medical professionals. Its primary products are UroShield; PainShield; and WoundShield. Each of its UroShield, PainShield, and WoundShield products employs a small, disposable transducer that transmits low-frequency, low-intensity ultrasound acoustic waves that seek to repair and regenerate tissue, musculoskeletal and vascular structures, and decrease biofilm formation on urinary catheters and associated urinary tract infections. The company derives revenues from selling its products directly to patients, through distributor agreements.